Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexajoint Max
- Development stage
- Unknown
- Lead developer
- BioElite
- Modality
- Classical Binding Small Molecules → Small Molecules, Peptides, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Hexajoint Max is a multi-ingredient oral combination therapy developed and marketed by BioElite Life Sciences, primarily for the management of osteoarthritis and other degenerative joint conditions. The formulation typically combines structural building blocks of joint tissue, including **glucosamine sulfate**, **chondroitin sulfate**, and **undenatured collagen type II**, with **hyaluronic acid** to support synovial lubrication. Additionally, it contains **Boswellia serrata extract**, which acts as a natural anti-inflammatory agent by inhibiting the 5-lipoxygenase (5-LOX) enzyme. Together, these ingredients work synergistically to reduce joint pain, decrease inflammation, and support the maintenance and repair of articular cartilage.
- Brand names
- Hexajoint Max
- Other names
- Hexajoint Max
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on Hexajoint Max.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hexajoint Max.